News and Press Releases

Evolva strengthens in-silico capabilities with acquisition of Prosarix

Cambridge, UK, August 4th 2014 — Evolva Holding SA (SIX: EVE) has today announced the acquisition of Prosarix Ltd.

Evolva and Prosarix have worked extensively together on multiple projects and products for eight years, in a progressively more integrated manner. This ever-deepening collaboration led both companies to conclude that a full combination and alignment of interests was the next logical step in furthering the relationship.

Prosarix’s capabilities will be integrated into all Evolva current and future projects and partnerships. Examples of areas where Prosarix’s technologies complement Evolva’s include:

  • Algorithmic optimization of gene libraries used in Evolva’s proprietary combinatorial pathway technologies
  • In-silico prediction of natural ingredient functions – f.x. how ingredients will taste based on their interaction with receptors in the tongue, nose or GI tract
  • Optimization of specific enzymes to overcome pathway flux bottlenecks or reduce unwanted side-products that may complicate down-stream purification

Commitments to Prosarix’s existing customers and partners will be fulfilled. Prosarix’s operations near Cambridge UK will be maintained and Prosarix employees will become Evolva employees.

About Evolva

Evolva is a pioneer and global leader in sustainable, fermentation-based approaches to ingredients for health, wellness and nutrition. Evolva’s products include stevia, vanilla, saffron and resveratrol. As well as developing its own proprietary ingredients, Evolva also deploys its technology for partners, providing them with a competitive edge and sharing in the returns they make. For more information see

For Evolva's Press release, please see Evolva Press Release.


©Prosarix 2007-2020

℅ RxCelerate Ltd, Moneta B280, Babraham Research Park, Cambridge, CB22 3AT ¦ +44 (0)1223 839557 ¦ ¦ legal